Clear cell chondrosarcoma in Von Hippel-Lindau disease.


Journal

Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 2 11 2019
medline: 9 2 2021
entrez: 2 11 2019
Statut: ppublish

Résumé

A diagnosis of clear cell chondrosarcoma of the ulna was made in a patient with Von Hippel-Lindau disease (VHL). After surgery, genetic analysis of the tumor tissue showed loss of heterozygosity at the VHL gene locus. Immunohistochemical analysis confirmed loss of expression of the VHL protein in the tumor cells. In addition, abundant Cyclin D1 expression in the tumor was observed. Chondrosarcoma has been described before in a VHL patient and VHL protein expression has been correlated to tumor grade in a series of sporadic chondrosarcomas. In this report, we show that clear cell chondrosarcoma may be a rare but canonical VHL manifestation through a cell-autonomous mechanism involving somatic loss-of-heterozygosity of the VHL tumor suppressor gene. We discuss the relevance of this observation with regard to the pathogenesis of clear cell chondrosarcoma in the context of VHL.

Identifiants

pubmed: 31673890
doi: 10.1007/s10689-019-00149-1
pii: 10.1007/s10689-019-00149-1
pmc: PMC7026311
doi:

Substances chimiques

Cyclin D1 136601-57-5
Von Hippel-Lindau Tumor Suppressor Protein EC 2.3.2.27
VHL protein, human EC 6.3.2.-

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-45

Références

Science. 1993 May 28;260(5112):1317-20
pubmed: 8493574
Am J Pathol. 1998 Jul;153(1):223-31
pubmed: 9665483
J Bone Joint Surg Am. 2011 Oct 5;93(19):1833-40
pubmed: 22005870
Nat Genet. 2013 Aug;45(8):923-6
pubmed: 23770606
Mol Cell Biol. 2005 Jul;25(13):5675-86
pubmed: 15964822
Curr Opin Oncol. 2016 Jul;28(4):314-22
pubmed: 27166664
Genes Chromosomes Cancer. 2012 Oct;51(10):899-909
pubmed: 22674453
J Exp Clin Cancer Res. 2007 Dec;26(4):599-601
pubmed: 18365559
Nat Rev Cancer. 2008 Nov;8(11):865-73
pubmed: 18923434

Auteurs

Koen M A Dreijerink (KMA)

Department of Internal Medicine, Amsterdam University Medical Centers, Location VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. k.dreijerink@amsterdamumc.nl.
Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. k.dreijerink@amsterdamumc.nl.

Rachel S van Leeuwaarde (RS)

Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Wenzel M Hackeng (WM)

Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Rachel H Giles (RH)

Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Wendy W J de Leng (WWJ)

Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Paul C Jutte (PC)

Department of Orthopedics, University Medical Center Groningen, Groningen, The Netherlands.

Albert J H Suurmeijer (AJH)

Department of Pathology, University Medical Center Groningen, Groningen, The Netherlands.

Bernadette P M van Nesselrooij (BPM)

Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.

Lodewijk A A Brosens (LAA)

Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH